FibroBiologics closes $3.0 million private placement priced at-the-market

FibroBiologics, Inc. (NASDAQ: FBLG) closed a private placement on June 29, 2026, after entering into a Securities Purchase Agreement on June 25, 2026 with a single accredited investor. The company received gross proceeds of $3,000,000 in exchange for pre-funded warrants in lieu of shares to purchase up to 4,081,633 shares of common stock, warrants to purchase up to 4,081,633 shares at an exercise price of $0.735 per share that are exercisable after stockholder approval and expire 18 months later, and separate warrants to purchase up to 4,081,633 shares also at $0.735 per share that expire five years after stockholder approval.¹

The offering was priced at-the-market under Nasdaq rules at $0.735 per share of common stock or per pre-funded warrant in lieu thereof, but the pre-funded warrants themselves carry an exercise price of $0.00001 per share, may be exercised starting on the issuance date, and do not expire.¹

The company offered pre-funded warrants instead of common stock because a share purchase would have pushed the investor, together with affiliates, above 9.99% beneficial ownership of outstanding common stock immediately after the offering.¹

Net proceeds to the company were approximately $2.6 million after placement agent fees and offering expenses.¹ If the warrants are fully exercised for cash following stockholder approval, the company could receive additional gross proceeds of about $6.0 million, though it cannot predict whether or when that exercise will occur.¹

H.C. Wainwright & Co., LLC acted as exclusive placement agent, receiving a 7.0% cash fee, a 1.0% management fee, $50,000 in reimbursed legal fees, and warrants to purchase up to 285,714 shares of common stock at $0.9188 per share.¹

The company said it plans to use net proceeds for working capital and general corporate purposes.¹ A related Form D filing confirmed the total offering amount and total amount sold as $3,000,000, with $0 remaining to be sold.²